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Abstract
Background: Human primary monocytes are refractory to infection with the human immunodeficiency virus 1 (HIV-1) or
transduction with HIV-1-derived vectors. In contrast, efficient single round transduction of monocytes is mediated by
vectors derived from simian immunodeficiency virus of sooty mangabeys (SIVsmmPBj), depending on the presence of the
viral accessory protein Vpx.
Methods and Findings: Here we analyzed whether Vpx of SIVsmmPBj is sufficient for transduction of primary monocytes by
HIV-1-derived vectors. To enable incorporation of PBj Vpx into HIV-1 vector particles, a HA-Vpr/Vpx fusion protein was
generated. Supplementation of HIV-1 vector particles with this fusion protein was not sufficient to facilitate transduction of
human monocytes. However, monocyte transduction with HIV-1-derived vectors was significantly enhanced after delivery of
Vpx proteins by virus-like particles (VLPs) derived from SIVsmmPBj. Moreover, pre-incubation with Vpx-containing VLPs
restored replication capacity of infectious HIV-1 in human monocytes. In monocytes of non-human primates, single-round
transduction with HIV-1 vectors was enabled.
Conclusion: Vpx enhances transduction of primary human and even non-human monocytes with HIV-1-derived vectors,
only if delivered in the background of SIVsmmPBj-derived virus-like particles. Thus, for accurate Vpx function the presence
of SIVsmmPBj capsid proteins might be required. Vpx is essential to overcome a block of early infection steps in primary
monocytes.
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Introduction
Compared to more differentiated cells of the hematopoietic
lineage such as macrophages or dendritic cells (DCs), human
primary monocytes are relatively refractory to HIV-1 infection in
vitro [1,2]. Likewise, lentiviral vectors derived from HIV-1 are not
able to mediate efficient monocyte transduction, whereas trans-
duction of monocyte-derived macrophages was possible at low
levels [1,3]. The reason for this difference is not clearly
understood. HIV-1 vectors pseudotyped with the envelope
glycoprotein of vesicular stomatitis virus (VSV) retain this different
transduction capacity for monocytes or macrophages [1],
suggesting that the block in monocytes is independent of viral
entry by attachment to CD4 or HIV-1 coreceptors. In some
studies the block is described as occurring prior to reverse
transcription [4,5], while others suggest that in monocytes an early
post entry block occurs shortly after reverse transcription [5,6]. At
least the viral cDNA synthesis and integration seem to be per se
extremely inefficient in monocytes since differentiation-dependent
cofactors of reverse transcription might be limited [4,7]. After
differentiation of monocytes into DCs, vectors that had already
entered the cells were rescued, whereat activation might have
induced accumulation of nuclear viral DNA [1]. Different activity
of cellular restriction factors like APOBEC proteins [8–10] may
contribute to the different susceptibility of monocytes and more
differentiated cells to HIV-1.
Recently, we described efficient transduction of primary human
monocytes using lentiviral vectors derived from the simian
immunodeficiency virus strain SIVsmmPBj isolated from sooty
mangabeys [3]. This capacity of SIVsmmPBj vectors depends on
the viral protein Vpx, whereas all other accessory genes are
dispensable [11]. A vector mutant designated PBj4xko-EGFP,
which lacks expression of the accessory genes vif, vpr, vpx and nef
was not capable of monocyte transduction. However, this capacity
could be restored by supplementation of the PBj4xko-EGFP vector
with Vpx [3,11]. The Vpx protein is encoded by viruses of the
HIV-2/SIVsmm/SIVmac lineage and it has been previously
described that replication of these viruses or efficient transduction
of macrophages or dendritic cells (DCs) with respective vectors
strictly depends on the presence of this viral protein [3,11–15]. A
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Vpx protein with the inability of mutant viruses to infect non-
dividing cells, thus arguing for its role in nuclear import, similar to
Vpr of HIV-1 [12,16–18]. To investigate whether Vpx is the only
factor required for monocyte transduction with lentiviral vectors,
we previously attempted to package Vpx of SIVsmmPBj into HIV-
1 particles [11]. In order to achieve this, the p6 domain of the
HIV-1 Gag protein was modified to allow binding and packaging
of Vpx. However, the resulting Vpx-containing HIV-1 vector
particles did not facilitate a more efficiently transduction of
primary monocytes than the unmodified HIV-1 vector. The block
occurred after reverse transcription of vector RNA and before
translocation of the pre-integration complex (PIC) into the
nucleus, similar to that shown for HIV-1 vectors or for PBj-
derived vectors lacking Vpx [1,3,11,19]. We concluded that Vpx
might not be present in the HIV-1 PIC, when delivered with the
modified HIV-1 particles, since Vpx may require specific binding
to other virus-specific components like integrase, MA or RNA.
In the present study, two further strategies were conducted to
confer Vpx properties to HIV-1-derived vectors. At first, a HA-
Vpr/Vpx fusion protein was generated to link Vpx function to the
HIV-1 counterpart Vpr in order to mediate packaging of Vpx via
Vpr into HIV-1 vector particles and subsequent targeting to the
PIC. Furthermore, we attempted to provide Vpx by preincubation
of target cells with virus like particles (VLPs) containing Vpx. We
analyzed whether Vpx functions enabled single-round infection
and full replication of HIV-1 in human and simian monocytes.
The results indicate that abolition of the HIV-1 restriction block in
monocytes is enabled by Vpx but also requires SIVsmmPBj Gag
or Pol functions.
Results
Packaging of SIVsmmPBj Vpx into HIV-1-derived particles
using Vpr-Vpx fusion proteins
Previously, we have shown that the Vpx protein of SIVsmmPBj
is not incorporated into unmodified HIV-1 vector particles [11]. A
modified HIV-1 vector, which carried the Vpx interaction domain
of the PBj Gag protein within the corresponding HIV p6 domain,
was able to package Vpx. However, this Vpx-containing HIV-1
vector was not able to transduce primary human monocytes [11].
Monocyte transduction was achieved when the SIVsmmPBj-
derived PBj4xko-EGFP was supplemented with the Vpx protein in
trans. As the HIV-1 counterpart protein Vpr is packaged during
virus budding into the particle and is part of the HIV-1 PIC [20],
we aimed to enable co-localization of Vpx with HIV-1 Vpr in the
target cell by generating a fusion protein consisting of HIV-1 Vpr
and PBj Vpx. Schematic representations of the HA-tagged fusion
construct as well as of the Vpr and Vpx proteins are shown in
Fig. 1A.
For generation of HIV-1 vector particles, 293T cells were co-
transfected with the transfer vector pHR-CMV-EGFP (Fig. 1B),
the packaging construct pCMVDR8.9 (Fig. 1C), the VSV-G
expression plasmid pMD.G and an expression vector encoding for
HA-Vpr, Vpx, or HA-Vpr/Vpx fusion protein. SIVsmmPBj
vectors were generated likewise but using the vector PBj4xko-
EGFP lacking all accessory genes (Fig. 1B). Vector particles were
harvested from supernatant, purified by sucrose gradient centri-
fugation, and analyzed by Western-blotting for the presence of the
respective Vpx or HA-Vpr proteins (Fig. 1D). The HA-Vpr/Vpx
fusion protein was detected at similar proportions in HIV-1- and
Figure 1. Schematic representation of expression constructs and packaging of Vpr/Vpx fusion proteins into vector particles was
detected by Western-blotting. (A) The viral proteins HIV-1 Vpr, SIVsmmPBj1.9 Vpx and related fusion proteins encoded by the expression vector
pcDNA3.1. For generation of the fusion protein, the full length Vpx was ligated to HIV-1 Vpr. HA, hemagglutinin tag. (B) HIV-1- or SIVsmmPBj- derived
transfer vectors coding for EGFP. In the PBj4xko-EGFP vector, coding regions of all four accessory genes are knocked-out by insertion of stop-codons
marked by an asterisk. (C) PBj- and HIV-1-derived packaging constructs coding for Gag-Pol and the regulatory proteins Tat and Rev. These constructs
were also used for production of virus-like particles. For pseudotyping of vectors or virus-like particles, the vesicular stomatitis virus G protein (VSV-G,
not shown) was used. (D) Western blots of supernatants or lysates of 293T packaging cells cotransfected with the respective vector constructs
required for generation of VSV-G-pseudotyped lentiviral vectors (HIV-1 LV or PBj4xko LV), and one of the expression constructs encoding Vpr, Vpx or
the Vpr/Vpx fusion protein as indicated on the top. As controls, supernatants and lysates of cells transfected only with one of the Vpr, Vpx or Vpr/Vpx
constructs were analyzed. Cell supernatants were purified by filtering and sucrose cushion centrifugation. For labelling, antibodies directed against
HA, Vpx, or the envelope protein VSV-G were used. Y, packaging signal; LTR, long terminal repeat; SD, splice donor; cPPT, central polypurine tract;
RRE, rev responsive element; SA, splice acceptor; CMV, cytomegalovirus promoter; BGHpA, bovine growth hormone polyadenylation signal.
doi:10.1371/journal.pone.0007098.g001
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or HA-Vpr/Vpx proteins in the supernatant fraction indicated
successful packaging into vector particles, as in the absence of the
Gag-Pol and the envelope constructs none of those proteins were
detected. In lysates of packaging cells, comparable expression
levels of the respective proteins were determined independently
from the presence or absence of the packaging and envelope
expression constructs.
To demonstrate integrity of the generated fusion protein, the
subcellular localization was analyzed in HeLa cells. In the absence
of other viral proteins, HA-tagged Vpr, Vpx and the Vpr/Vpx
fusion protein are localized in the nucleus (supplementary Fig. S1),
as previously described for similar constructs [12,16,21,22]
indicating that localization of the fusion protein as a prerequisite
of Vpx function is retained.
HIV-1 vector particles supplemented with the HA-Vpr/
Vpx fusion protein are not able to transduce primary
human monocytes
To investigate the capacity of HA-Vpr/Vpx containing HIV-1-
derived vectors to transduce primary human monocytes, these
cells were isolated from blood of healthy donors by negative
depletion and analyzed by FACS for expression of the surface
marker CD14. Routinely, the purity of the monocyte population
was about 90% (data not shown). Purified cells were transduced at
various days post isolation with an MOI of 10 using VSV-G
pseudotyped SIVsmmPBj- or HIV-1-derived vector particles
supplemented with the HA-Vpr/Vpx fusion protein, HA-Vpr or
wild-type Vpx. At the first time point of transduction at day two
after isolation, the cells are quiescent monocytes as confirmed by
low DNA/RNA content [3].Three days after cultivation, the cells
start to differentiate to macrophages, as indicated by increased
DNA/RNA content, decreased expression of CD86 surface
marker and change of morphology [3], and are designated as
monocyte-derived cells. Independent of the day of transduction,
application of PBj4xko-EGFP vector particles containing the HA-
Vpr/Vpx fusion protein resulted in an approximately 10-fold
higher transduction rate, compared to non-supplemented vector
(Fig. 2A). The observed transduction efficiency was comparable to
that of PBj4xko-EGFP vectors supplemented with wild-type Vpx,
indicating that the generated HA-Vpr/Vpx fusion protein is
entirely functional. In contrast, HIV-1 vectors containing the HA-
Vpr/Vpx fusion protein were not capable of transducing primary
human monocytes or monocyte-derived cells with higher efficiency
than non-supplemented particles (Fig. 2B). These results indicate
that further PBj-specific factors in addition to the Vpx protein
might be required for efficient transduction of primary human
monocytes.
Vpx provided by SIVsmmPBj-derived virus-like particles
enables HIV-1 vectors to transduce primary human
monocytes
Since packaging of Vpx into HIV-1 vector particles did not
result in enhanced monocyte transduction, we attempted to
provide Vpx by preincubation of monocytes with Vpx-containing
virus-like particles. The VLPs were generated by transfection of
293T cells with the SIV-PBj-derived packaging construct pPBj-
psi10 lacking all accessory genes (Fig. 1C), the VSV-G expression
construct pMD.G and an expression construct encoding wild-type
Vpx (Fig 1A). VLPs were purified from supernatant of transfected
cells by sucrose gradient centrifugation, and the presence of Vpx
was proven by Western blotting (Fig. 3A). To quantify VLPs,
Reverse transcriptase activity was determined and compared to
that of PBj vectors of known infectivity on HT1080 cells, assuming
that RT activity is equal for infectious and non-infectious particles
generated using the same vector genome. Accordingly, after
preincubation of target cells with VLPs, the number of VLPs per
cell was given as MOI-equivalents (MOIeq). Successive transduc-
tion experiments with monocytes using an HIV-1-derived
encoding EGFP vector were carried out as described above, but
monocytes or monocyte-derived cells were pre-incubated for two
hours prior to transduction with VLPs at an MOIeq of 1 (Fig. 3B).
Now, efficient transduction with HIV-1 vectors was observed with
efficiencies slightly lower than those reached with the positive
control vector PBjDE-EGFP containing a functional Vpx. Pre-
incubation with VLPs not supplemented with Vpx did not
enhance transduction of monocytes or monocyte-derived cells
with the HIV-1-derived vector. Transduction of monocytes with
PBj4xko-EGFP vector particles was also achieved by pre-
incubation of cells with Vpx-containing VLPs (Fig. 3C).
To determine a potential influence of Vpx on differentiation
and/or activation of the cells, the surface expression of CD11c,
CD14, CD86, DC-SIGN and MHCII was analyzed. Monocytes
or monocyte-derived cells were incubated at various days after
isolation for 48 h with VLPs carrying Vpx or not and analyzed by
FACS (Fig. 3D). The slight overall decrease of CD11c, CD14 and
CD86 suggested differentiation of monocytes to macrophages
during the observation period [23,24] which was confirmed by
absence of the dendritic marker DC-SIGN. The antigen
Figure 2. Packaging of Vpx into vector particles enhances
transduction by SIVsmmPBj-derived but not HIV-1-derived
vectors. Percentage of EGFP-expressing monocytes or monocyte-
derived cells transduced at various days post isolation using VSV-G
pseudotyped vector particles (MOI 10) supplemented with Vpx, Vpr, or
the Vpr/Vpx fusion protein as indicated. The percentage of EGFP-
expressing cells was determined by flow cytometry 6 days post
transduction. (A) Transduction efficiency of PBj4xko-EGFP-derived
vector particles. (B) Transduction efficiency of HIV-1-derived vector
particles. Positive control: PBDE-EGFP-derived vector containing all
accessory genes. Means of three different donors are shown.
doi:10.1371/journal.pone.0007098.g002
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CD86 were slightly increased on cells treated at d5 with Vpx-
supplemented VLP, indicating a possible Vpx-dependent activa-
tion. However, beside these exceptions only marginal differences
were detected between untreated and VLP-treated cells. In
particular, d2 cells which are most relevant since they are clearly
monocytes showed identical expression patterns after treatment
with Vpx-carrying or empty VLPs, indicating that differentiation
or activation of monocytes by Vpx plays only a minor role for
transduction, if any.
To describe the effect in dependence of the amount of viral
particles, either the amount of vectors or that of VLPs was varied.
Figure 3. Vpx-containing SIVsmmPBj-derived VLPs enhance transduction with HIV-1 vectors. (A) Packaging of Vpx into PBj-derived VLPs
was detected by Western-blotting. VLPs were generated by cotransfection of the PBj packaging vector pPBj-psi10 and the VSV-G and Vpx expression
plasmids. Forty-eight hours post transfection, vector containing supernatant was collected from the 293T cells, filtered and purified twice by
ultracentrifugation through a sucrose cushion. Purified VLPs were analyzed on Western blots using antibodies directed against Vpx or the envelope
protein VSV-G. (B, C) Transduction of primary human monocytes or monocyte-derived cells 2 h after pre-incubation with Vpx-containing or non-
containing PBj-derived VLPs (VLP(PBj)) at an MOIeq of 1 (determined by RT-Assay with standards of known infectivity) as indicated. Percentage of
EGFP-expressing cells transduced at various days after isolation using (B) HIV-1 vectors or (C) PBj4xko-EGFP vectors. The percentage of transduced
cells was determined by flow cytometry 6 days post transduction. The means of two different donors are shown. (D) Influence of Vpx on activation
and differentiation of monocytes or monocyte-derived cells. At the indicated day after isolation, cells were incubated for 48 h with VLPs
supplemented with Vpx (+VLPs +Vpx) or not (+VLPs 2Vpx) at an MOIeq of 1, in comparison with untreated cells (2VLPs). The surface expression of
the markers indicated was determined by FACS analysis. One representative donor out of three is shown.
doi:10.1371/journal.pone.0007098.g003
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of monocytes. An enhancing effect was already obtained at an
MOIeq of 0.1. This effect increased dose-dependently up to an
MOIeq of about 1 (Fig. 4A). Next, monocytes were preincubated
with VLPs at an MOIeq of 1 and subsequently transduced using
different amounts of HIV-1-derived vector particles (Fig. 4B).
Transduction rates increased with increasing vector MOI. The
highest transduction rate of about 50% was reached with an MOI
of 10. In contrast, no transduction was detected after preincuba-
tion of monocytes with VLPs lacking Vpx, even at an MOI of
HIV-1 vector particles of 10. Transduction efficiency increased
only if higher amounts of HIV-1 vector particles were used. The
maximum transduction efficiency of about 50% in the presence of
Vpx was achieved with an MOI of 10, and in the absence of Vpx
with an MOI of 100.
Since single round transduction with HIV-1-derived vectors is
enabled by pre-delivery of SIV Vpx, we analyzed whether Vpx
also facilitates full HIV-1 replication in these cells. Monocytes
were pre-incubated at day 1 post isolation with PBj-derived VLPs
either containing or lacking Vpx at an MOIeq of 1 for two hours
and subsequently infected with the CCR5-tropic HIV-1 virus
strain SF162 at an low MOI of 0.5. Replication was determined by
measuring RT-activity in the supernatant of infected cells for 18
days. SIVsmmPBj1.9 wild-type virus which encodes Vpx and is
known to efficiently replicate in primary macrophages [12,15,25]
was used as a control. The replication capacity of the HIV-1 virus
was completely rescued when monocytes were treated with Vpx
containing VLPs, and was comparable to that of SIVsmmPBj1.9
on untreated cells. In contrast, HIV-1 did not replicate in
untreated cells or after pre-incubation with VLPs not containing
Vpx (Fig. 4C).
Vpx provided by SIVsmmPBj-derived VLPs enables HIV-1
vectors to transduce primary simian monocytes
With the exception of chimpanzees, non-human primates are
naturally resistant to HIV-1 infection [26–29]. Restriction of HIV-
1 infection in rhesus macaque cells in vitro has been attributed to a
post-entry step, perhaps due to cellular restriction factors like
TRIM5a or APOBEC proteins [30], whereas TRIM5a restriction
has been described to be absent in Pig-tailed macaques [31]. Here,
we investigated whether Vpx-containing VLPs can overcome these
restrictions and enable transduction of simian monocytes with
HIV-1-derived vectors. Monocytes of rhesus macaques (Macaca
mulatta) or Pig-tailed macaques (Macaca nemestrina) were
isolated, pre-incubated after two days with PBj-derived VLPs at
an MOIeq of 1, and subsequently transduced with PBj4xko-
EGFP- or HIV-1-derived vectors at an MOI of 8. Efficient
transduction of non-human primate monocytes was achieved
Figure 4. Enhancement of HIV-1 transduction of monocytes by PBj-derived VLPs is dose-dependent and enables replication of HIV-
1 on human monocytes. Percentage of EGFP-expressing cells 6 days post transduction. (A) Monocytes (day 2 post isolation) were pre-incubated
for 2 h with increasing amounts of PBj-derived VLPs (VLP(PBj)) as indicated, and transduced with HIV-1 vectors at an MOI of 10. (B) Monocytes were
incubated with PBj-derived VLPs at an MOIeq of 1 (determined by RT-Assay with standards of known infectivity), followed by transduction with HIV-1
vectors at increasing MOI as indicated. The means of two different donors are shown. (C) On day 1 post isolation, monocytes were incubated for 2 h
with Vpx-containing or non-containing VLPs at an MOIeq of 1 and subsequently infected with CCR5-tropic HIV-1 strain SF165 at an MOI of 0.5.
SIVsmmPBj1.9 infection was performed without previous VLP incubation. Replication kinetics of HIV-1 or SIVsmmPBj after pre-incubation of
monocytes with VLPs as indicated. Virus replication was assessed by quantifying RT activity in cell culture supernatants. Means of two different
donors from one representative out of three experiments are shown.
doi:10.1371/journal.pone.0007098.g004
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VLPs (Fig. 5A). The transduction efficiency was comparable to
that of the SIVsmmPBj-derived PBj4xko-EGFP vector on Pig-
tailed macaque monocytes, although the transduction capacity of
rhesus macaque cells was slightly higher. In contrast, pre-
incubation with VLPs lacking Vpx did not significantly increase
HIV-1 transduction of simian monocytes. These results indicate
that Vpx allows single-round infection of non-human primate cells
with an HIV-1-derived vector.
Next we analyzed whether overcoming this first blocks of
infection would allow HIV-1 replication of HIV-1 wild-type virus
on non-human monocytes. Monocytes isolated from Pig-tailed
macaques were stimulated for 8 h with TPA to enhance
attachment and growth of cells. On day 1 post isolation,
monocytes were pre-incubated with Vpx-supplemented or non-
supplemented PBj VLPs at an MOIeq of 1 for two hours, and
subsequently infected with the CCR5-tropic HIV-1 virus strain
SF162 at an MOI of 0.5. Replicating SIVsmmPBj virus was used
as control. Replication was determined by measuring RT activity
levels in the supernatant of infected cells for 21 days. Results
demonstrated that replication of the HIV-1 virus did not occur in
monocyte-derived cells of Pig-tailed macaques (Fig. 5B), although
single round infections of HIV-1 vectors was enabled in the
presence of Vpx. Full replication was observed in control cells
infected with SIVsmmPBj1.9 (Fig. 5B).
Discussion
The data presented here emphasizes the essential role of Vpx
during the infection of primary monocytes by lentiviral viruses.
Primary human monocytes are relatively refractory to single round
infection or full replication of HIV-1 [1,3], albeit efficient infection
of monocytes, DCs or macrophages can be achieved by using high
amounts of input virus [23,32,33]. We described recently that
transduction of monocytes with vectors derived from SIVsmmPBj
[3,11] is clearly enhanced in the presence of the viral protein Vpx,
which is not encoded by the genome of HIV-1. To determine
whether Vpx is the single factor within the SIVsmmPBj derived
virus required for transduction of quiescent cells like monocytes,
we decided to assign the functional activities of Vpx to HIV-1. To
Figure 5. Vpx enables single-round but not full replication of HIV-1 in non-human primate monocytes. (A) Transduction of simian
monocytes. Monocytes from Rhesus or Pig-tailed macaques were pre-incubated for 2 h with PBj-derived VLPs either containing or lacking Vpx at an
MOIeq of 1, and subsequently transduced with HIV-1 or PBj4xko-EGFP vectors at an MOI of 7 as indicated. Means of three animals of each species are
shown. (B) Replication kinetics of HIV-1 or SIVsmmPBj. Monocytes of Pig-tailed macaques were stimulated at day 1 post isolation for 8 h with TPA
before incubation with VLPs as indicated at an MOIeq of 1, and subsequent infected an MOI of 0.5 with HIV-1 strain SF165 or SIVsmmPBj1.9. Virus
replication was assessed by quantifying RT antigen in cell culture supernatants. Means of three different donors out of two independent experiments
are shown.
doi:10.1371/journal.pone.0007098.g005
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generated a chimeric HIV-1 vector harboring the p6 domain of
the SIVsmmPBj virus. However, Vpx did not enhance transduc-
tion of monocytes with this chimeric HIV-1 vector, although
efficient packaging was demonstrated [3,11]. The block occurred
after reverse transcription of vector RNA and before translocation
of the PIC into the nucleus, similar to that previously described for
HIV-1 wild-type vectors or for SIVsmmPBj vectors lacking Vpx
[1,3,11,19]. We considered that Vpx might not be present in the
HIV-1 PIC to enable trafficking of the PIC into the nucleus, since
Vpx requires interaction with other virus specific components such
as integrase, MA or RNA. Therefore, two further strategies were
pursued to assign functional activities of Vpx to HIV-1-derived
vectors. First, we achieved packaging into HIV-1 vector particles
by fusing PBj Vpx to HIV-1 Vpr, generating a HA-Vpr/Vpx
fusion protein. Like Vpx, Vpr has been described to be present in
the PIC and thus might transfer the Vpx protein into the HIV-1
PIC [12,16–18]. Translocation of the PIC into the nucleus can
directly be linked to the nuclear localization of Vpx and Vpr
[34,35], and this capacity was retained for the fusion protein HA-
Vpr/Vpx. Furthermore, the Vpx part within the HA-Vpr/Vpx
fusion protein was still functional in terms of enabling efficient
transduction of monocytes, as proven in the context of the
PBj4xko-EGFP vector. However, the fusion protein HA-Vpr/Vpx
did not enhance transduction of monocytes or monocyte-derived
cells if packaged into an HIV-1 vector. We concluded that beside
Vpx, other viral components of the PBj-virus are required for
efficient monocyte transduction.
Secondly, we used virus-like particles to assign Vpx functions to
HIV-1-derived vectors, thus allowing monocyte transduction.
Goujon et al. showed that SIVmac Vpx can be functionally
provided in trans by pre-incubation of dendritic cells (DCs) with
non-infectious SIVmac-derived virus-like particles (VLPs), which
were simply used as carriers of the Vpx proteins [13,14]. We
investigated the suitability of SIVsmmPBj Vpx-containing VLPs
derived from SIVsmmPBj to enhance transduction of monocytes
by HIV-1 vectors. Remarkably, upon pre-incubation with Vpx-
supplemented SIVsmmPBj-derived VLPs, the transduction effi-
ciency of HIV-1 vectors was enhanced 10-fold, which is in line
with a very recent publication [36]. By using increasing amounts
of VLPs, we could show that the transduction efficiency was dose-
dependent. Transduction with HIV-1 vectors was also mediated
when the PBj-derived VLPs were supplemented with the HA-
Vpr/Vpx fusion protein, but not by supplementation of HIV-1-
derived VLPs with HA-Vpr/Vpx (data not shown). Thus, as
already concluded from the transduction experiments using Vpx
directly packaged into HIV-1 vector particles, it is evident that the
Vpx protein is only capable of mediating monocyte transduction if
it is delivered in the background of SIVsmmPBj capsids. Whether
SIVsmmPBj capsid components are required for efficient release
of Vpx from the particles to the cytoplasm, for a certain activation
of Vpx, or for nuclear localization of the PIC, remains still elusive.
In contrast to our findings, Sharova et al. [37] observed an
enhancing effect when Vpx was co-packaged into HIV-1 particles.
In this case, no further viral components of SIVsmmPBj were
necessary, indicating that the restriction mechanism described by
Sharova et al. for macrophages may be different from the
restriction block present in monocytes investigated by us. In our
hands, packaging of Vpx into HIV-1 particles was only possible
after insertion of the p6 domain into the HIV-1 genome [11] or
after fusion of Vpx to Vpr, thus preventing direct comparison of
the function of Vpx-containing HIV-1 particles.
Remarkably, PBj Vpx did also enable full replication of HIV-1
wild-type virus on human monocytes. Single pre-incubation of
monocytes with PBj-derived Vpx-supplemented VLPs was suffi-
cient to promote full replication of a CCR5-tropic HIV-1 virus
comparable to that of SIVsmmPBj1.9 wild-type virus encoding
Vpx. There are several possible explanations for this observation.
It might be possible that the initial infection step during virus
replication is most crucial and that once it has entered the nucleus
the virus may efficiently replicate in the infected cell. Another
explanation might be that Vpx has a sustained effect in the target
cells, allowing several rounds of infection. This hypothesis is
supported by our own observations that Vpx containing VLPs,
delivered to monocytes 20 h before the HIV-1-derived vector still
enabled efficient single round transduction (data not shown).
Possible modes of action of Vpx could be by counteracting the
function of cellular antiviral genes, or induction of important
cofactors lacking in monocytes and required e.g. for cell cycle
progression [38,39]. However, surface marker expression indica-
tive for induction of differentiation or activation like CD11c,
CD14, CD86, DC-SIGN or MHC-II were not or only marginally
influenced by Vpx provided by VLPs, especially at day two after
isolation when all of the cells are still monocytes. Similar results
have been described for dendritic cells treated with Vpx [13].
Therefore, we suggest that counteraction of cellular antiviral
genes, rather than induction of differentiation or activation,
constitutes the functionality of Vpx.
Several proteins mediating retroviral post-entry and post-
integration blocks of HIV-1 in monocytes or DCs have been
described. As the suppression of protein expression by specific
siRNAs against different members of the APOBEC family, namely
A3G, A3A and A3F, restored the susceptibility of monocytes and
DCs to HIV-1 infection [6,10,40], we analyzed the influence of
Vpx on APOBEC expression. Recent experiments indicated that
pre-incubation of monocytes with Vpx-supplemented PBj-VLPs
did not alter either mRNA levels of A3G, A3A, A3F, A3C or
Trim5ahu, protein levels of A3A or A3G, although the
transduction efficiency of HIV-1 was significantly enhanced (data
not shown). From these experiments we concluded that Vpx may
not act as a direct antagonist of APOBEC proteins. APOBEC3G
has been described to impair the initiation of HIV-1 reverse
transcription and/or processivity of reverse transcription [41]. The
accumulation of RT products in DCs was strongly enhanced in the
presence of Vpx [13,14,42,43], which indicates that Vpx
counteracts the restriction during reverse transcriptions. Since
transduction of monocytes was also enhanced when the Vpx
containing VLPs were added up to 20 h post HIV-1 transduction
(data not shown), it might be likely that the restriction occurs just
before translocation of the PIC in the nucleus or even in the
nucleus, before integration. However, it remains still elusive in
which way Vpx might counteract different APOBEC or Trim5a
restriction pathways, considering that we have not observed a
change in APOBEC gene expression.
For non-human primate cells, additional species specific pre-
and post- integration blocks of retroviruses, such as Trim5a have
been described [29,44–46]. To analyze, whether Vpx does
circumvent restriction of HIV-1 in non-human primate cells, we
isolated CD14
+ cells from rhesus macaques or Pig-tailed
macaques. In Pig-tailed macaque cells, HIV-1 infection is not
restricted by Trim5a as in rhesus macaque cells [31]. Remarkably,
we could show an enhanced transduction of monocytes from both
simian species using HIV-1-derived vectors. Pre-incubation with
VLPs not supplemented with Vpx did not increase HIV-1
transduction efficiency. Thus a simple saturation of restriction
factors by Gag or Pol proteins such as described for simian Trim5a
[47,48] can be excluded. Vpx allowed a single-round infection of
non-human primate monocytes but did not enable full replication
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tested. We conclude that the Vpx protein counteracts restriction of
early steps in HIV-1 infection, such as entry, reverse transcription
[14] or nuclear import [35,49], in human as well in non-human
primate monocytes. In human monocytes, this is sufficient for
complete virus replication. However, HIV-1 replication is not
enabled in non-human primate monocytes, which may be
attributed to other post-integration blocks of HIV-1 replication
which are not counteracted by Vpx, such as simian APOBEC
proteins [44,50].
We suggest that the function of Vpx is to antagonize an antiviral
restriction factor present in primary human monocytes. Single-
round and productive infection by HIV-1 can be attained by
providing the PBj Vpx protein in trans using PBj-derived but not
HIV-1-derived particles, the molecular basis for this specificity
remains unknown. Using Vpx-supplemented PBj-derived VLPs,
the early restriction block of HIV-1 is also circumvented in non-
human primate monocytes. However, additional post-integrations
blocks not present in human monocytes restrict full virus
replication.
Materials and Methods
Plasmids
The env-deficient SIVsmmPBj1.9 vector constructs pPBjDE-
EGFP and pPBj4xko-EGFP, as well as the expression constructs
pcHA-Vpx and pcwt-Vpx were described previously [3,11]. The
HIV-1-derived transfer vector plasmid pHR-CMV-EGFP [51]
and the respective packaging construct pCMVdR8.9 [52] were
kindly provided by U. Blo ¨mer. The SIVsmmPBj1.9-derived
packaging construct PBj-psi10 is based on the env-deleted
molecular clone pPBjDenv [3]. For construction of PBj-psi10, a
CMV promoter was used to replace the 59 LTR, and the 39 LTR
was replaced with the bovine growth hormone polyadenylation
site using BsaB I and Not I restriction sites. The accessory genes vif,
vpx, vpr and nef were deleted by applying fusion PCR, while the
regulatory genes tat and rev were maintained. Furthermore, 155 bp
between the CMV promoter and the major splice donor (SD) site
as well as 59 bp between SD and gag were deleted by fusion PCR,
preserving exclusively the primer binding site and the SD. Primer
sequences are available upon request.
The HA-Vpr/Vpx-expression construct was compiled by fusing
PCR fragments generated from HIV-1-NL4-3 and SIVsmmPBj1.9
DNA using 59 CGC GGATCC GCC ACC ATG TAC CCC
TAC GAC GTG CCC GAC TAC GCC GGC GAA CAA GCC
CCA GAA GAC 39 (forward) and 59 CCT GGG ATC TGA CAT
GCC GCC GGA TCT ACT GGC TCC ATT TCT39-39
(reverse) primers to amplify the Vpr encoding region Vpr and 59
AAT GGA GCC AGT AGA TCC GGC GGC ATG TCA GAT
CCC AGG GAG A 39 (forward) and 59 CCG CTC GAG TTA
TGC TAG TCC TGG AGG GGG AGG AG 39 (reverse) to
amplify the Vpx encoding region, respectively. For fusion of the
obtained Vpr and Vpx specific PCR products, the Vpr specific
forward primer and the Vpx-specific reverse primer were applied.
The amplification product spanning the respective HA-Vpr/Vpx
encoding gene was inserted into the mammalian expression vector
pcDNA3.1(+) (Invitrogen, Carlsbad, CA, USA) using the restric-
tion sites BamH I and Xho I. All expression constructs were
confirmed by DNA sequence analysis (MWG Biotech, Ebersberg,
Germany).
Cell lines
293T (ATCC; SD 3515), HT1080 (ATCC; CCL121) and HeLa
(ATCC CCL-2) were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with penicillin (100 U/ml),
streptomycin (100 mg/ml), L-glutamine (2 mM) and 10% FCS.
Generation and titration of vector and virus-like particles
For generation of SIVsmmPBj-derived vectors, 293T cells were
co-transfected with one of the vector-encoding plasmids described
above and pMD.G [53] coding for the vesicular stomatitis virus
glycoprotein G (VSV-G) by the calcium phosphate transfection
method. HIV-1-derived vectors were generated likewise but using
the vector encoding plasmid pHR-CMV-EGFP and the packaging
construct pCMVDR8.9. For production of PBj- or HIV-1-derived
VLPs, the respective packaging construct was co-transfected with
pMD.G. For supplementation of SIVsmmPBj1.9 or HIV-1 vectors
or VLPs with Vpx, HA-Vpr or HA-Vpr/Vpx, the respective
expression plasmid was additionally co-transfected into vector
producing cells. After 48 hours, the vector containing supernatants
were collected, filtrated (0.45 mm filter, Sartorius, Go ¨ttingen,
Germany), concentrated by ultracentrifugation (125,000 x g, 2 h,
4uC) through a 20% sucrose cushion and subsequently stored at
280uC. For titration, vectors were added in serial dilutions to
permissive HT1080 cells seeded in 24-well plates. After 4 h,
culture medium was exchanged. Four days later, cells were
monitored for EGFP expression by FACS analysis. The amount of
VLPs was determined by Lenti RT Activity kit (Cavidi AB,
Uppsala, Sweden) and normalized in comparison to PBj- or HIV-
1-vectors of known infectivity. For incubation experiments, the
amount of VLPs per cell was given as MOI-equivalents (MOIeq).
Isolation, transduction and infection of primary human
and simian monocytes
Primary human CD14
+ monocytes were isolated from purified
PBMC from healthy donors by negative depletion, and monocytes
of rhesus macaques or Pig-tailed macaques by positive selection
employing magnetic activated cell sorting (MACS) using the
Monocyte Isolation Kit II or the isolation Kit for non-human
primate cells, respectively (Miltenyi Biotec, Bergisch Gladbach,
Germany). Housing of monkeys and blood donation was
maintained in accordance with the German animal license
regulations (Tierschutzgesetz). Purity of isolated monocytes was
assessed by flow cytometry (FACScan
TM, Becton Dickinson)
analysing expression of the monocyte marker CD14 using a
specific phycoerythrin-conjugated monoclonal antibody (BD
Bioscience, Heidelberg, Germany). Monocytes were seeded at a
density of 4610
5 cells/well into 48-well tissue culture plates (BD
Falcon, Bedford, MA, USA) and maintained in VLE-RPMI1640
(Biochrom AG, Berlin, Germany) supplemented with penicillin
(100 U/ml), streptomycin (100 mg/ml), L-glutamine (2 mM), non
essential amino acids (Gibco), 10 ml/L OPI (oxaloacetic acid,.
pyruvate and insulin; SIGMA-Aldrich, Taufkirchen, Germany)
and 10% human-AB serum (Biochrom AG, Berlin, Germany). For
cultivation of simian cells, culture medium was supplied with 10%
autologous serum. In some experiments, at the desired day after
isolation, monocytes or monocyte-derived cells were pre-exposed
for two hours to VLPs where the amount of VLPs per cell was
given as MOI-equivalents (MOIeq). For transduction, cells were
exposed for 4 h to SIVsmmPBj1.9- or HIV-1-derived vectors.
EGFP expression of vector-transduced cells was measured by
FACS analysis 6 days post transduction. For analysis of virus
replication, monocytes were infected in triplicate on day 1 post
isolation with an MOI of 0.5 with HIV-1 or SIVsmmPBj strains
and cultured up to day 21. Before infection with the respective
wild type viruses, non-human primate cells were pre-stimulated for
8 h with 20 ng/ml TPA. To determine the amount of
SIVsmmPBj and HIV-1, supernatants (200 ml) were collected
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Lenti RT Activity kit (Cavidi AB, Uppsala, Sweden).
For determination of cell surface marker expression, primary
monocytes were isolated as described above and seeded at a
density of 3610
6 cells/well into 6-well tissue culture plates (BD
Falcon, Bedford, MA, USA). On day 2, 5 and 9 post isolation, cells
were cultivated for 48 h in the presence of PBj-derived VLPs at an
MOIeq of 1. The cells were stained with aCD11c-FITC (Acris
GmbH, Herford, Germany) aCD14-PE (DAKO, Hamburg,
Germany), aCD86-PE (BD-Pharmingen, Heidelberg, Germany),
aCD209-FITC (Milteny Biotec, Bergisch Gladbach, Germany) or
aMHC-II-FITC (DAKO) and analyzed by flow cytometry (LSR
II; Becton Dickinson, Heidelberg, Germany). During data analysis
with FCS-Express (DeNovo Software, Los Angeles, USA) the
isotype controls were matched.
Detection of virion proteins by Western blotting
Vector or VLP-containing supernatants were clarified by
filtration (0.45 mm filter) and concentrated by ultracentrifugation
through a 20% sucrose cushion (125,000 x g, 2 h, 4uC).
Subsequently, viral particles were resuspended in 1 ml of PBS
(4uC) and ultracentrifuged through 12 ml of a 20% sucrose
cushion (140,000 x g, 1 h, 4uC).
For Western blot analysis, vector particles were resuspended in
ice-cold lysis buffer (50 mM HEPES [pH 7.4], 125 mM NaCl,
0.1 mM phenylmethylsulphonyl fluoride, 0.2% NP40), and
transfected 293T cells were lysed in ice-cold RIPA buffer (Tris
50 mM, NaCl 150 mM, SDS 0.1%, Na-Deoxycholate 0.5%,
0.1 mM phenylmethylsulphonyl fluoride, NP40 1%), both sup-
plemented with protease inhibitor cocktail (Roche, Mannheim,
Germany). Cell lysates were additionally sonicated and protein
concentrations were determined by the Bradford method.
Samples were denatured (95uC, 5 min) and separated on
NuPAGE Novex 4–12% SDS-polyacrylamide gels (Invitrogen,
Carlsbad, CA, USA). Following electrophoresis, proteins were
transferred to Hybond ECL nitrocellulose membrane (GE
Healthcare, Mu ¨nchen, Germany) by electroblotting, incubated
in blocking buffer (5% nonfat dry milk in PBS, 0.1% Tween 20) at
room temperature for 1 h and then over night at 4uC with the
appropriate primary antibody. Anti-HIV-2-Vpx monoclonal
antibody (NIH AIDS Research and Reference Reagent Program,
Rockville, USA) was used 1:50, anti-HA monoclonal antibody
(Covance, Princeton, NJ, USA) was diluted 1:5,000 and anti VSV-
G (SIGMA-Aldrich, Taufkirchen, Germany) was diluted 1:10,000.
Protein-bound antibodies were detected with HRP-conjugated
specific secondary antibodies (diluted 1:7,500 respectively),
followed by enhanced chemiluminescence analysis (GE Health-
care, Mu ¨nchen, Germany).
Supporting Information
Figure S1 HA-tagged Vpr, Vpx and the Vpr/Vpx fusion
protein are localized in the nucleus. HeLa cells transfected using
FuGENE reagent with the expression constructs indicated on the
left. Two days after transfection, cells were fixed in 4%
paraformaldehyde, permeabilized in 0.1% Triton-X-100, and
blocked with Image-iT. The HA-tagged Vpx, Vpr or Vpr/Vpx
fusion protein were stained with an anti-HA antibody. Monoclonal
secondary antibody anti-mouse Alexa Fluor 488, was used
together with a Rhodamine Phalloidine solution. Subsequently,
4,6-diamidino-2-phenylindole staining was performed. Finally,
cells were embedded in Mowiol and analyzed by confocal laser
scanning microscopy. (a-HA) Indirect immunofluorescence using
anti-HA antibodies and Alexa Fluor 488 conjugated secondary
antibody. (DAPI) Staining of nuclei by 4, 6-diamidino-2-
phenylindole. (Rhodamin) Staining of cytoplasmatic microfila-
ments by rhodamin-phalloidine.
Found at: doi:10.1371/journal.pone.0007098.s001 (3.09 MB TIF)
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